Moberg Pharma and Karo Healthcare Expand Collaboration via Cross-Border E-Commerce to Enter China
Moberg Pharma and Karo Healthcare announced an expansion of their cooperation to introduce antifungal drug MOB-015 into the Chinese market through cross-border e-commerce.
重要な事実は何ですか？
- 1Entering China via cross-border e-commerce
- 2Product is antifungal drug MOB-015
- 3Previously covered multiple European and Asia-Pacific markets
何が起きたのですか？
Moberg Pharma and Karo Healthcare have reached an agreement to sell the antifungal drug MOB-015 in China via cross-border e-commerce channels. This collaboration previously covered Europe, Australia, New Zealand, and Taiwan, and choosing cross-border e-commerce as the initial entry point into China aims for rapid market validation and deployment.
越境ECセラーにとって何を意味しますか？
Cross-border e-commerce has become the preferred pathway for pharmaceutical and health brands entering the Chinese market. Sellers should pay attention to the operational models of these compliant cross-border channels, as cross-border e-commerce offers a low-barrier entry point for overseas brands aspiring to enter the Chinese market.